Bartlett & CO. Wealth Management LLC Reduces Position in Bristol-Myers Squibb (NYSE:BMY)

Bartlett & CO. Wealth Management LLC decreased its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 9.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 172,563 shares of the biopharmaceutical company's stock after selling 18,148 shares during the quarter. Bartlett & CO. Wealth Management LLC's holdings in Bristol-Myers Squibb were worth $8,928,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Capital International Investors boosted its stake in Bristol-Myers Squibb by 14.1% during the 1st quarter. Capital International Investors now owns 70,203,814 shares of the biopharmaceutical company's stock valued at $3,807,153,000 after purchasing an additional 8,675,322 shares during the period. M&G Plc bought a new stake in shares of Bristol-Myers Squibb in the 1st quarter valued at about $392,608,000. Pzena Investment Management LLC increased its stake in Bristol-Myers Squibb by 119.8% during the 1st quarter. Pzena Investment Management LLC now owns 12,293,913 shares of the biopharmaceutical company's stock worth $666,699,000 after purchasing an additional 6,701,097 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Bristol-Myers Squibb by 77.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,547,823 shares of the biopharmaceutical company's stock worth $680,469,000 after acquiring an additional 5,461,767 shares in the last quarter. Finally, Van ECK Associates Corp boosted its holdings in shares of Bristol-Myers Squibb by 97.2% in the 1st quarter. Van ECK Associates Corp now owns 7,949,173 shares of the biopharmaceutical company's stock valued at $431,084,000 after buying an additional 3,918,234 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol-Myers Squibb Trading Up 0.1 %

Shares of NYSE BMY traded up $0.04 during trading on Friday, reaching $53.22. The company had a trading volume of 7,184,496 shares, compared to its average volume of 14,752,302. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $57.09. The company has a quick ratio of 1.02, a current ratio of 1.16 and a debt-to-equity ratio of 2.86. The company's fifty day moving average price is $50.36 and its 200-day moving average price is $46.37. The stock has a market cap of $107.88 billion, a P/E ratio of -17.17, a PEG ratio of 13.75 and a beta of 0.46.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.64 by $0.43. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The company had revenue of $12.20 billion during the quarter, compared to analyst estimates of $11.54 billion. During the same quarter last year, the company earned $1.75 earnings per share. The firm's quarterly revenue was up 8.7% on a year-over-year basis. As a group, research analysts expect that Bristol-Myers Squibb will post 0.77 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 4.51%. The ex-dividend date of this dividend is Friday, October 4th. Bristol-Myers Squibb's dividend payout ratio is presently -77.42%.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on BMY shares. Cantor Fitzgerald restated a "neutral" rating and issued a $50.00 price target on shares of Bristol-Myers Squibb in a research report on Friday. Barclays increased their price target on Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an "underweight" rating in a research report on Monday, October 7th. StockNews.com upgraded Bristol-Myers Squibb from a "buy" rating to a "strong-buy" rating in a research note on Monday, July 29th. Jefferies Financial Group lifted their price target on Bristol-Myers Squibb from $49.00 to $51.00 and gave the company a "hold" rating in a research report on Wednesday, August 28th. Finally, TD Cowen lifted their price target on Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a "hold" rating in a research note on Monday, October 7th. Two research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $53.20.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.